Comparative Pharmacology
Head-to-head clinical analysis: CO GESIC versus DARVOCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO GESIC versus DARVOCET.
CO-GESIC vs DARVOCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Darvocet is a combination of propoxyphene, a mu-opioid receptor agonist that alters perception of and response to pain, and acetaminophen, which inhibits COX enzymes and modulates descending serotonergic pathways.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
1 tablet (propoxyphene 100 mg / acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Propoxyphene: 6-12 hours (parent), 30-36 hours (norpropoxyphene). Acetaminophen: 1-4 hours (therapeutic doses). Accumulation of norpropoxyphene occurs with repeated dosing.
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Propoxyphene: primarily hepatic metabolism to norpropoxyphene, renal excretion of metabolites (<1% unchanged). Acetaminophen: renal excretion of conjugates (85-90%) and unchanged drug (2-4%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination